Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors
Open Access
- 1 August 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (16) , 14016-14039
Abstract
HDAC8 can mediate signals by using its enzymatic or nonenzymatic functions, which are expected to be critical for various types of cancer. Herein, we employed proteolysis targeting chimera (PROTAC) technology to target the enzymatic as well as the nonenzymatic functions of HDAC8. A potent and selective HDAC8 PROTAC Z16 (CZH-726) with low nanomolar DC50 values in various cell lines was identified. Interestingly, Z16 induced structural maintenance of chromosomes protein 3 (SMC3) hyperacetylation at low concentrations and histone hyperacetylation at high concentrations, which can be explained by HDAC8 degradation and off-target HDAC inhibition, respectively. Notably, Z16 potently inhibited proliferation of various cancer cell lines and the antiproliferative mechanisms proved to be cell-type-dependent, which, to a large extent, is due to off-target HDAC inhibition. In conclusion, we report a hydrazide-based HDAC8 PROTAC Z16, which can be used as a probe to investigate the biological functions of HDAC8.Keywords
Funding Information
- Fourth Framework Programme (101080889)
- China Scholarship Council (202006220019, 202008420244, 202107060008)
This publication has 67 references indexed in Scilit:
- Cell deathCell, 2024
- Discovery of highly potent HDAC8 PROTACs with anti-tumor activityBioorganic Chemistry, 2023
- Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's PerspectiveAngewandte Chemie International Edition, 2020
- Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein DegradationCell Chemical Biology, 2018
- Lessons in PROTAC Design from Selective Degradation with a Promiscuous WarheadCell Chemical Biology, 2018
- Small‐Molecule PROTACS: New Approaches to Protein DegradationAngewandte Chemie International Edition, 2016
- Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors—What Some May Have Forgotten or Would Rather Forget?ChemMedChem, 2015
- Histone deacetylase inhibitors and cell deathCellular and Molecular Life Sciences, 2014
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)Cancer Chemotherapy and Pharmacology, 2010